Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting

Summary

This trial is conducted in the United States of America (USA). The purpose of the trial is to investigate the effect and safety of liraglutide 3.0 mg as an adjunct to intensive behaviour therapy for obesity in a non-specialist setting (IBT-CMS: Intensive Behaviour Therapy for obesity in a primary care setting according to Centers for Medicare \& Medicaid Services (CMS) visit schedule).

Timeline

Start

2017-02-06

Primary completion

2018-05-23

Completion

2018-06-19

Outcome

Met primary endpoint

registry analysis (superiority test); Liraglutide 3.0 mg vs Placebo; p = 0.0003; Treatment difference -3.45 (95% CI -5.31 to -1.59); ANCOVA NCT02963935 ↗

registry analysis (superiority test); Liraglutide 3.0 mg vs Placebo; p = 0.0003; Odds Ratio (OR) 2.51 (95% CI 1.53 to 4.14); Regression, Logistic NCT02963935 ↗

Publications

• Results Wadden TA, Tronieri JS, Sugimoto D, Lund MT, Auerbach P, Jensen C, Rubino D. Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial. Obesity (Silver Spring). 2020 Mar;28(3):529-536. doi: 10.1002/oby.22726.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Liraglutide	Peptide	3 mg	Subcutaneous

Indications